netupitant palonostron (Akynzeo)

following a full submission

netupitant/palonosetron (Akynzeo®) is accepted for restricted  use within NHS Scotland.

Indication under review: in adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy.

SMC restriction: prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy.

In patients receiving a first course of highly emetogenic cisplatin-based chemotherapy, treatment with netupitant/palonosetron plus dexamethasone resulted in a significantly higher proportion of patients achieving no emesis and no breakthrough medication compared with palonosetron plus dexamethasone.

This advice takes account of the benefits of Patient Access Scheme (PAS) that improves the cost-effectiveness of netupitant/palonosetron.  This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.